Liver cirrhosis can develop as a consequence of chronic hepatitis, a fatty liver or alcohol abuse. Liver cells are destroyed and replaced by connective tissue.
Detailed description
Symptoms of liver cirrhosis may include dysfunctions of blood clotting and of the detoxification function as well as yellowing of the skin, weight loss and itching. The regeneration of tissue can lead to liver cancer.
TherVacB, a novel therapeutic vaccine to combat chronic hepatitis B, entered the first clinical trial. The vaccine was designed and developed under the leadership of Helmholtz Munich. This phase Ia
In a multicentre phase 3 trial, researchers at the MHH have demonstrated the efficacy and safety of the drug Bulevirtide, which prevents Hepatitis D viruses from entering the liver.
Approximately 300 million people worldwide are chronically infected with the hepatitis B virus (HBV) and at high risk of developing liver cirrhosis or hepatocellular carcinoma. Consequently, there is
Please use this image only in connection to this press release.
Hepatitis B virus (HBV) infections remain a major global health problem – according to the World Health Organization (WHO) there are around 300 million HBV carriers worldwide. Current treatments
Stephan Urban, DZIF professor at Heidelberg University Hospital, receives the Baruch S. Blumberg Prize 2023 from the Hepatitis B Foundation, a global non-profit organisation. The virologist is being
Please use this image only in connection with this press release.
Around 300 million people are living with a chronic hepatitis B virus (HBV) infection and currently there is no cure for the disease. A team of researchers around DZIF professor Ulrike Protzer from
Between 10 and 20 million people worldwide are infected with hepatitis D virus (HDV). HDV infection is always associated with hepatitis B virus infection. So far there has been no satisfactory
